• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Australian Radiology Centre Sonic Imaging to Implement Annalise.ai’s Chest X-Ray Platform

Share:

September 29, 2021

Sonic Imaging, one of Australia’s largest diagnostic imaging providers, has partnered with annalise.ai to deploy the latters’ artificial intelligence-powered chest x-ray platform across its 100 radiology clinics.

WHAT IT DOES

Founded in 2019, annalise.ai is a joint venture of two Australian healthcare companies, Harrison.ai and I–MED Radiology Network.

The AI company is the developer of the Annalise CXR, which they claim is the only comprehensive AI clinical support solution for chest x-rays in the world that detects 124 findings – to compare, typical chest x-ray AI products on the market can detect fewer than 15 findings. Its model was based on over 520,000 chest x-ray studies, comprising over 820,000 individual images. The datasets were labeled by a group of 148 radiologists.

Annalise CXR is available for clinical use in Australia, New Zealand, the UK, Malaysia, and Europe. It is now being used by around three in 10 Australian radiologists, annalise.ai says.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The company is now looking to scale its offering as it enters more European and Asian markets this year.

MARKET SNAPSHOT

There have been significant developments in the AI imaging market in the Asia-Pacific this year. Beijing-headquartered SenseTime in April got a CE mark for its AI diagnostic software for chest x-rays. Lunit, a South Korean startup, has recently received Singapore’s approval to market its AI diagnostic tool for chest radiographs while Fujifilm Corporation has also secured Japan’s approval for its own AI diagnostic software.

Another South Korean AI developer, VUNO, has partnered with Samsung Electronics for the integration of its AI-enabled chest x-ray diagnostic solution with the latter’s premium mobile digital radiograph system.

According to research firm MarketsandMarkets, the global market for AI in medical diagnostics might reach $3.9 billion in value by 2025 from $505 million last year, growing at a CAGR of 50.2%.

ON THE RECORD

Sonic Imaging CEO Julian Adler explained why they chose annalise.ai as its preferred decision support AI provider: “We determined that the Annalise Enterprise Platform is category-leading in its comprehensiveness and offers Sonic the premier AI platform we are seeking for [a] chest x-ray, with a strong roadmap across multiple modalities.”

“The fact that radiologists and clinicians are heavily involved in solutions development and deployment is obvious, resulting in an intuitive product that radiologists appreciate. The implementation of the Annalise Enterprise Platform contributes to our ongoing commitment to patient safety and reporting quality at Sonic Imaging Australia,” he added.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Extherid Biosciences has merged with Perfectus Biomed in the UK to form Perfectus Biomed GroupExtherid Biosciences has merged with Perfectus Biomed in the UK to form Perfectus Biomed Group
  • Amazon is turning its controversial Rekognition software to medical image redactionAmazon is turning its controversial Rekognition software to medical image redaction
  • Brachytherapy catheters Market Insights, Potential Business Strategies, Mergers and Acquisitions, Revenue Analysis – 2020– 2028Brachytherapy catheters Market Insights, Potential Business Strategies, Mergers and Acquisitions, Revenue Analysis – 2020– 2028
  • Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, CanadaOcugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada
  • Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative DiseasesLilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
  • London-Based uMed Secures $4.8M to Automate & Advance Clinical Research RegistriesLondon-Based uMed Secures $4.8M to Automate & Advance Clinical Research Registries
  • Mylan Skyrockets After Securing a Merger With Pfizer’s Off-Patent Drug UnitMylan Skyrockets After Securing a Merger With Pfizer’s Off-Patent Drug Unit
  • Aveanna Healthcare to Acquire Maxim Healthcare Services’ Home Healthcare DivisionAveanna Healthcare to Acquire Maxim Healthcare Services’ Home Healthcare Division

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications